Mindset Pharma Receives Another Allowance from USPTO for Patent Application Expanding Composition of Matter for Family 1 Psilocybin Analogs
Mindset Pharma Inc. (CSE: MSET) (OTCQB: MSSTF) announced that the United States Patent and Trademark Office has allowed a new patent application, number 17/743,718, covering psilocin derivatives for treating CNS disorders. This marks the fourth patent allowance for Mindset, enhancing its intellectual property portfolio. The Family 1 patent includes psilocybin-inspired candidates with improved pharmacokinetics and safety profiles. The priority date for this application is February 4, 2020. The company focuses on developing next-generation psychedelic medicines for neuropsychiatric disorders.
- Grant of patent allowance for new psilocin derivatives enhances intellectual property.
- Mindset now holds four patent allowances, strengthening its market position.
- Psilocybin-inspired candidates show improved pharmacokinetics and safety profiles.
- None.
TORONTO, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, announced today that the United States Patent and Trademark Office (“USPTO”) has granted allowance for another of Mindset’s Family 1 patent applications, number 17/743,718, titled “Psilocin Derivatives As Serotonergic Psychedelic Agents for the Treatment of CNS Disorders.” Included in this patent are certain deuterated psilocybin analogs from Family 1.
“We are pleased to announce that Mindset has received yet another allowance from the USPTO. This marks Mindset’s fourth allowance of composition of matter intellectual property (IP) rights for our growing IP portfolio,” said James Lanthier, CEO of Mindset Pharma. “Now, our Family 1 is covered by 3 patent allowances, further enhancing the strategic positioning of Family 1 and reaffirming its commercial potential.”
Family 1 consists of psilocybin-inspired drug candidates that demonstrate improved pharmacokinetic, efficacy and safety profiles, with reduced potential side effects and evidence of increased target engagement, in pre-clinical studies. This application is one of a family of applications having a priority date of February 4, 2020.
About Mindset Pharma Inc.
Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic and non-psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs. Mindset was established in order to develop next-generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next-generation psychedelic compounds, as well as an innovative process and cost-effective to chemically synthesize psilocybin in addition to its own proprietary compounds. The company has a co-development agreement with the McQuade Center for Strategic Research and Development, a member of the Otsuka Pharmaceuticals family of companies, for its short-duration compounds, Mindset Families 2 & 4.
For further information on Mindset, please visit our website at www.mindsetpharma.com.
For more information, please contact:
Investor Contact:
Allison Soss
KCSA Strategic Communications
Email: MindSet@kcsa.com
Phone: 212-896-1267
Media Contact:
McKenna Miller
KCSA Strategic Communications
Email: MindSet@kcsa.com
Phone: 949-606-6585
Company Contact:
James Lanthier, CEO
Email: jlanthier@mindsetpharma.com
Jason Atkinson, VP, Corporate Development
Email: jatkinson@mindsetpharma.com
Phone: 416-479-4094
Forward-Looking Information
This news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "would", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Forward-looking information is based on the opinions and estimates of management at the date the information is provided and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Additional information regarding risks and uncertainties relating to the Company's business are contained under the heading "Risk Factors" in the Company's annual information form for the financial year ended June 30, 2020 dated March 5, 2021. The forward-looking information included in this news release is made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise, except as required by applicable law.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPTED RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
FAQ
What is the recent patent allowance announced by Mindset Pharma?
How many patent allowances does Mindset Pharma currently have?
What benefits do Mindset's psilocybin-inspired drug candidates offer?
When was the priority date for Mindset's latest patent application?
What focus does Mindset Pharma have in drug development?
